Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAND: PaMZ for DS-TB and MDR-TB
NCT02342886Phase 3Completed
- Sponsor
- TB Alliance
- Start
- Feb 2015
- Primary completion
- Jan 2018
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of pretomanid in pulmonary tuberculosis (TB) (5 arms), sponsored by TB Alliance. Primary endpoint: Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at 12 months. Started Feb 2015; status: completed.
02
Drugs
pretomanid
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT02342886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342886.